Does the media refer more to TECX or NKTR?

In the previous week, Nektar Therapeutics had 6 more articles in the media than Tectonic Therapeutic. MarketBeat recorded 14 mentions for Nektar Therapeutics and 8 mentions for Tectonic Therapeutic. Nektar Therapeutics' average media sentiment score of 0.68 beat Tectonic Therapeutic's score of 0.31 indicating that Nektar Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tectonic Therapeutic 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Nektar Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive

Is AMLX or TECX more profitable?

Tectonic Therapeutic's return on equity of -34.35% beat Amylyx Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Amylyx Pharmaceuticals N/A -52.92% -48.53% Tectonic Therapeutic N/A -34.35% -32.80%

Does the media favor AMLX or TECX?

In the previous week, Amylyx Pharmaceuticals had 9 more articles in the media than Tectonic Therapeutic. MarketBeat recorded 17 mentions for Amylyx Pharmaceuticals and 8 mentions for Tectonic Therapeutic. Tectonic Therapeutic's average media sentiment score of 0.31 beat Amylyx Pharmaceuticals' score of 0.13 indicating that Tectonic Therapeutic is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amylyx Pharmaceuticals 3 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Tectonic Therapeutic 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor BCRX or TECX?

In the previous week, BioCryst Pharmaceuticals had 7 more articles in the media than Tectonic Therapeutic. MarketBeat recorded 15 mentions for BioCryst Pharmaceuticals and 8 mentions for Tectonic Therapeutic. BioCryst Pharmaceuticals' average media sentiment score of 0.48 beat Tectonic Therapeutic's score of 0.31 indicating that BioCryst Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioCryst Pharmaceuticals 5 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Tectonic Therapeutic 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to TECX or PGEN?

In the previous week, Precigen had 2 more articles in the media than Tectonic Therapeutic. MarketBeat recorded 10 mentions for Precigen and 8 mentions for Tectonic Therapeutic. Precigen's average media sentiment score of 0.74 beat Tectonic Therapeutic's score of 0.31 indicating that Precigen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tectonic Therapeutic 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Precigen 2 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings & valuation, TECX or KLRA?

Tectonic Therapeutic is trading at a lower price-to-earnings ratio than Kailera Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Tectonic Therapeutic N/A N/A -$74.15M -$4.57 N/A Kailera Therapeutics N/A N/A -$148.96M -$3.65 thousand N/A

Is TECX or KLRA more profitable?

Kailera Therapeutics' return on equity of 0.00% beat Tectonic Therapeutic's return on equity. Company Net Margins Return on Equity Return on Assets Tectonic Therapeutic N/A -34.35% -32.80% Kailera Therapeutics N/A N/A N/A

Does the media refer more to TECX or KLRA?

In the previous week, Tectonic Therapeutic had 3 more articles in the media than Kailera Therapeutics. MarketBeat recorded 8 mentions for Tectonic Therapeutic and 5 mentions for Kailera Therapeutics. Tectonic Therapeutic's average media sentiment score of 0.31 beat Kailera Therapeutics' score of -0.09 indicating that Tectonic Therapeutic is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tectonic Therapeutic 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Kailera Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Tectonic Therapeutic (TECX) Competitors

$34.97 +0.99 (+2.90%)

As of 02:34 PM Eastern

Compare

TECX vs. NKTR, AMLX, BCRX, PGEN, and KLRA

Should you buy Tectonic Therapeutic stock or one of its competitors? Tectonic Therapeutic's main competitors and comparable companies include Nektar Therapeutics (NKTR), Amylyx Pharmaceuticals (AMLX), BioCryst Pharmaceuticals (BCRX), Precigen (PGEN), and Kailera Therapeutics (KLRA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Tectonic Therapeutic compare to Nektar Therapeutics?

Tectonic Therapeutic (NASDAQ:TECX) and Nektar Therapeutics (NASDAQ:NKTR) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, valuation, profitability, risk, dividends, earnings and analyst recommendations.

Tectonic Therapeutic presently has a consensus target price of $77.80, indicating a potential upside of 124.82%. Nektar Therapeutics has a consensus target price of $150.00, indicating a potential upside of 99.35%. Given Tectonic Therapeutic's higher probable upside, analysts clearly believe Tectonic Therapeutic is more favorable than Nektar Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tectonic Therapeutic	2 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.75
Nektar Therapeutics	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75

62.6% of Tectonic Therapeutic shares are owned by institutional investors. Comparatively, 75.9% of Nektar Therapeutics shares are owned by institutional investors. 39.8% of Tectonic Therapeutic shares are owned by insiders. Comparatively, 2.5% of Nektar Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Tectonic Therapeutic has a beta of 3.28, suggesting that its share price is 228% more volatile than the broader market. Comparatively, Nektar Therapeutics has a beta of 1.14, suggesting that its share price is 14% more volatile than the broader market.

Tectonic Therapeutic has a net margin of 0.00% compared to Nektar Therapeutics' net margin of -284.18%. Tectonic Therapeutic's return on equity of -34.35% beat Nektar Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tectonic Therapeutic	N/A	-34.35%	-32.80%
Nektar Therapeutics	-284.18%	-85.40%	-39.99%

In the previous week, Nektar Therapeutics had 6 more articles in the media than Tectonic Therapeutic. MarketBeat recorded 14 mentions for Nektar Therapeutics and 8 mentions for Tectonic Therapeutic. Nektar Therapeutics' average media sentiment score of 0.68 beat Tectonic Therapeutic's score of 0.31 indicating that Nektar Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tectonic Therapeutic	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Nektar Therapeutics	4 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive

Tectonic Therapeutic has higher earnings, but lower revenue than Nektar Therapeutics. Nektar Therapeutics is trading at a lower price-to-earnings ratio than Tectonic Therapeutic, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tectonic Therapeutic	N/A	N/A	-$74.15M	-$4.57	N/A
Nektar Therapeutics	$55.23M	46.04	-$164.08M	-$8.42	N/A

Summary

Tectonic Therapeutic beats Nektar Therapeutics on 10 of the 15 factors compared between the two stocks.

How does Tectonic Therapeutic compare to Amylyx Pharmaceuticals?

Amylyx Pharmaceuticals (NASDAQ:AMLX) and Tectonic Therapeutic (NASDAQ:TECX) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, risk, earnings, media sentiment, profitability, dividends, valuation and institutional ownership.

95.8% of Amylyx Pharmaceuticals shares are owned by institutional investors. Comparatively, 62.6% of Tectonic Therapeutic shares are owned by institutional investors. 10.9% of Amylyx Pharmaceuticals shares are owned by insiders. Comparatively, 39.8% of Tectonic Therapeutic shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Amylyx Pharmaceuticals presently has a consensus target price of $25.38, indicating a potential upside of 17.22%. Tectonic Therapeutic has a consensus target price of $77.80, indicating a potential upside of 124.82%. Given Tectonic Therapeutic's higher probable upside, analysts clearly believe Tectonic Therapeutic is more favorable than Amylyx Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amylyx Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.90
Tectonic Therapeutic	2 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.75

Tectonic Therapeutic has lower revenue, but higher earnings than Amylyx Pharmaceuticals. Amylyx Pharmaceuticals is trading at a lower price-to-earnings ratio than Tectonic Therapeutic, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amylyx Pharmaceuticals	$87.37M	27.61	-$144.74M	-$1.43	N/A
Tectonic Therapeutic	N/A	N/A	-$74.15M	-$4.57	N/A

In the previous week, Amylyx Pharmaceuticals had 9 more articles in the media than Tectonic Therapeutic. MarketBeat recorded 17 mentions for Amylyx Pharmaceuticals and 8 mentions for Tectonic Therapeutic. Tectonic Therapeutic's average media sentiment score of 0.31 beat Amylyx Pharmaceuticals' score of 0.13 indicating that Tectonic Therapeutic is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amylyx Pharmaceuticals	3 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Tectonic Therapeutic	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Tectonic Therapeutic's return on equity of -34.35% beat Amylyx Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amylyx Pharmaceuticals	N/A	-52.92%	-48.53%
Tectonic Therapeutic	N/A	-34.35%	-32.80%

Amylyx Pharmaceuticals has a beta of -0.21, meaning that its stock price is 121% less volatile than the broader market. Comparatively, Tectonic Therapeutic has a beta of 3.28, meaning that its stock price is 228% more volatile than the broader market.

Summary

Tectonic Therapeutic beats Amylyx Pharmaceuticals on 9 of the 15 factors compared between the two stocks.

How does Tectonic Therapeutic compare to BioCryst Pharmaceuticals?

BioCryst Pharmaceuticals (NASDAQ:BCRX) and Tectonic Therapeutic (NASDAQ:TECX) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, media sentiment, dividends, earnings, risk, analyst recommendations, profitability and valuation.

BioCryst Pharmaceuticals has higher revenue and earnings than Tectonic Therapeutic. Tectonic Therapeutic is trading at a lower price-to-earnings ratio than BioCryst Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioCryst Pharmaceuticals	$940.61M	2.59	$263.86M	-$1.50	N/A
Tectonic Therapeutic	N/A	N/A	-$74.15M	-$4.57	N/A

BioCryst Pharmaceuticals has a beta of 0.55, suggesting that its share price is 45% less volatile than the broader market. Comparatively, Tectonic Therapeutic has a beta of 3.28, suggesting that its share price is 228% more volatile than the broader market.

In the previous week, BioCryst Pharmaceuticals had 7 more articles in the media than Tectonic Therapeutic. MarketBeat recorded 15 mentions for BioCryst Pharmaceuticals and 8 mentions for Tectonic Therapeutic. BioCryst Pharmaceuticals' average media sentiment score of 0.48 beat Tectonic Therapeutic's score of 0.31 indicating that BioCryst Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioCryst Pharmaceuticals	5 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Tectonic Therapeutic	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

BioCryst Pharmaceuticals presently has a consensus target price of $20.60, indicating a potential upside of 115.82%. Tectonic Therapeutic has a consensus target price of $77.80, indicating a potential upside of 124.82%. Given Tectonic Therapeutic's stronger consensus rating and higher probable upside, analysts plainly believe Tectonic Therapeutic is more favorable than BioCryst Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioCryst Pharmaceuticals	0 Sell rating(s)	4 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.67
Tectonic Therapeutic	2 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.75

Tectonic Therapeutic has a net margin of 0.00% compared to BioCryst Pharmaceuticals' net margin of -40.90%. Tectonic Therapeutic's return on equity of -34.35% beat BioCryst Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioCryst Pharmaceuticals	-40.90%	-86.89%	66.37%
Tectonic Therapeutic	N/A	-34.35%	-32.80%

85.9% of BioCryst Pharmaceuticals shares are held by institutional investors. Comparatively, 62.6% of Tectonic Therapeutic shares are held by institutional investors. 3.8% of BioCryst Pharmaceuticals shares are held by company insiders. Comparatively, 39.8% of Tectonic Therapeutic shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

BioCryst Pharmaceuticals beats Tectonic Therapeutic on 9 of the 16 factors compared between the two stocks.

How does Tectonic Therapeutic compare to Precigen?

Tectonic Therapeutic (NASDAQ:TECX) and Precigen (NASDAQ:PGEN) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, media sentiment, valuation, earnings, institutional ownership and dividends.

62.6% of Tectonic Therapeutic shares are owned by institutional investors. Comparatively, 33.5% of Precigen shares are owned by institutional investors. 39.8% of Tectonic Therapeutic shares are owned by insiders. Comparatively, 41.4% of Precigen shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Precigen had 2 more articles in the media than Tectonic Therapeutic. MarketBeat recorded 10 mentions for Precigen and 8 mentions for Tectonic Therapeutic. Precigen's average media sentiment score of 0.74 beat Tectonic Therapeutic's score of 0.31 indicating that Precigen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tectonic Therapeutic	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Precigen	2 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Tectonic Therapeutic has higher earnings, but lower revenue than Precigen. Tectonic Therapeutic is trading at a lower price-to-earnings ratio than Precigen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tectonic Therapeutic	N/A	N/A	-$74.15M	-$4.57	N/A
Precigen	$9.68M	226.69	-$250.64M	-$1.04	N/A

Tectonic Therapeutic currently has a consensus target price of $77.80, indicating a potential upside of 124.82%. Precigen has a consensus target price of $14.50, indicating a potential upside of 135.58%. Given Precigen's higher possible upside, analysts plainly believe Precigen is more favorable than Tectonic Therapeutic.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tectonic Therapeutic	2 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.75
Precigen	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67

Tectonic Therapeutic has a net margin of 0.00% compared to Precigen's net margin of -183.98%. Precigen's return on equity of 423.75% beat Tectonic Therapeutic's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tectonic Therapeutic	N/A	-34.35%	-32.80%
Precigen	-183.98%	423.75%	84.39%

Tectonic Therapeutic has a beta of 3.28, suggesting that its share price is 228% more volatile than the broader market. Comparatively, Precigen has a beta of 1.02, suggesting that its share price is 2% more volatile than the broader market.

Summary

Precigen beats Tectonic Therapeutic on 9 of the 16 factors compared between the two stocks.

How does Tectonic Therapeutic compare to Kailera Therapeutics?

Tectonic Therapeutic (NASDAQ:TECX) and Kailera Therapeutics (NASDAQ:KLRA) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, analyst recommendations, profitability, dividends and earnings.

In the previous week, Tectonic Therapeutic had 3 more articles in the media than Kailera Therapeutics. MarketBeat recorded 8 mentions for Tectonic Therapeutic and 5 mentions for Kailera Therapeutics. Tectonic Therapeutic's average media sentiment score of 0.31 beat Kailera Therapeutics' score of -0.09 indicating that Tectonic Therapeutic is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tectonic Therapeutic	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Kailera Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

62.6% of Tectonic Therapeutic shares are held by institutional investors. 39.8% of Tectonic Therapeutic shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Kailera Therapeutics' return on equity of 0.00% beat Tectonic Therapeutic's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tectonic Therapeutic	N/A	-34.35%	-32.80%
Kailera Therapeutics	N/A	N/A	N/A

Tectonic Therapeutic presently has a consensus target price of $77.80, suggesting a potential upside of 124.82%. Kailera Therapeutics has a consensus target price of $42.75, suggesting a potential upside of 139.76%. Given Kailera Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Kailera Therapeutics is more favorable than Tectonic Therapeutic.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tectonic Therapeutic	2 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.75
Kailera Therapeutics	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	3.00

Tectonic Therapeutic is trading at a lower price-to-earnings ratio than Kailera Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tectonic Therapeutic	N/A	N/A	-$74.15M	-$4.57	N/A
Kailera Therapeutics	N/A	N/A	-$148.96M	-$3.65 thousand	N/A

Summary

Tectonic Therapeutic beats Kailera Therapeutics on 7 of the 13 factors compared between the two stocks.

Get Tectonic Therapeutic News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TECX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TECX vs. The Competition

Export

Metric	Tectonic Therapeutic	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$676.53M	$3.70B	$6.98B	$13.02B
Dividend Yield	N/A	3.76%	2.58%	10.72%
P/E Ratio	-7.57	10.38	269.27	25.25
Price / Sales	N/A	1,292.94	597.31	101.05
Price / Cash	N/A	103.01	70.53	50.75
Price / Book	2.58	17.48	13.07	6.33
Net Income	-$74.15M	-$13.32M	$3.45B	$347.81M
7 Day Performance	11.70%	0.94%	0.74%	0.90%
1 Month Performance	-0.59%	0.76%	1.40%	0.89%
1 Year Performance	41.42%	54.88%	67.03%	20.36%

Tectonic Therapeutic Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TECX Tectonic Therapeutic	2.9978 of 5 stars	$34.97 +2.9%	$77.80 +122.5%	+53.8%	$678.35M	N/A	N/A	120
NKTR Nektar Therapeutics	2.8122 of 5 stars	$75.50 +0.9%	$150.00 +98.7%	+195.2%	$2.53B	$55.23M	N/A	220	Trending News Earnings Report
AMLX Amylyx Pharmaceuticals	2.5912 of 5 stars	$23.63 +4.2%	$25.38 +7.4%	+170.8%	$2.53B	$87.37M	N/A	200	News Coverage Analyst Revision
BCRX BioCryst Pharmaceuticals	2.337 of 5 stars	$10.34 +5.1%	$20.60 +99.2%	+15.0%	$2.51B	$874.84M	N/A	530	News Coverage Analyst Revision
PGEN Precigen	3.1071 of 5 stars	$6.86 -2.0%	$14.50 +111.4%	+239.8%	$2.50B	$9.68M	N/A	190	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TECX) was last updated on 8/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Tectonic Therapeutic (TECX) Competitors

TECX vs. NKTR, AMLX, BCRX, PGEN, and KLRA

How does Tectonic Therapeutic compare to Nektar Therapeutics?

Summary

How does Tectonic Therapeutic compare to Amylyx Pharmaceuticals?

Summary

How does Tectonic Therapeutic compare to BioCryst Pharmaceuticals?

Summary

How does Tectonic Therapeutic compare to Precigen?

Summary

How does Tectonic Therapeutic compare to Kailera Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TECX vs. The Competition

Tectonic Therapeutic Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Tectonic Therapeutic (TECX) Competitors

TECX vs. NKTR, AMLX, BCRX, PGEN, and KLRA

How does Tectonic Therapeutic compare to Nektar Therapeutics?

Do analysts recommend TECX or NKTR?

Do insiders and institutionals believe in TECX or NKTR?

Which has more volatility and risk, TECX or NKTR?

Is TECX or NKTR more profitable?

Does the media refer more to TECX or NKTR?

Which has better earnings and valuation, TECX or NKTR?

Summary

How does Tectonic Therapeutic compare to Amylyx Pharmaceuticals?

Do insiders & institutionals have more ownership in AMLX or TECX?

Do analysts rate AMLX or TECX?

Which has higher valuation and earnings, AMLX or TECX?

Does the media favor AMLX or TECX?

Is AMLX or TECX more profitable?

Which has more risk & volatility, AMLX or TECX?

Summary

How does Tectonic Therapeutic compare to BioCryst Pharmaceuticals?

Which has stronger earnings and valuation, BCRX or TECX?

Which has more risk & volatility, BCRX or TECX?

Does the media favor BCRX or TECX?

Do analysts rate BCRX or TECX?

Is BCRX or TECX more profitable?

Do institutionals and insiders have more ownership in BCRX or TECX?

Summary

How does Tectonic Therapeutic compare to Precigen?

Do insiders & institutionals have more ownership in TECX or PGEN?

Does the media refer more to TECX or PGEN?

Which has preferable valuation and earnings, TECX or PGEN?

Do analysts prefer TECX or PGEN?

Is TECX or PGEN more profitable?

Which has more volatility & risk, TECX or PGEN?

Summary

How does Tectonic Therapeutic compare to Kailera Therapeutics?

Does the media refer more to TECX or KLRA?

Do insiders & institutionals believe in TECX or KLRA?

Is TECX or KLRA more profitable?

Do analysts prefer TECX or KLRA?

Which has better earnings & valuation, TECX or KLRA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TECX vs. The Competition

Tectonic Therapeutic Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools